N-4-庚基哌啶 | 6220-95-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: N-4-庚基哌啶
• 英文名称: N-4-Heptylpiperidine
• 英文别名: 4-Piperidino-heptan；1-(1-propyl-butyl)-piperidine；1-(1-Propyl-butyl)-piperidin；1-Heptan-4-ylpiperidine
• CAS: 6220-95-7
• 化学式: C₁₂H₂₅N
• 分子量: 183.337
• InChiKey: RJGRLBGBKVKBGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  4-庚酮 在 tert-butylhypochloride 、 氨 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 N-4-庚基哌啶
  参考文献：
  名称：

  二丙基二嗪的光解和哌啶对二丙基卡宾的捕集

  摘要：

  二丙基二嗪在二氯甲烷中于4°C进行的光解（350 nm）产生E和Z 3-庚烯的混合物，产率为81％，比率为1.8。形成的四丙嗪的产率低于5％。在哌啶存在下二丙基二嗪碱的光解导致形成卡宾-胺加合物。在0.06 M哌啶的存在下，加合物的收率为48％，E和Z 3-庚烯的收率为47％，而3-庚烯的比例为1.1。结果表明，庚烯是由三个途径形成的。一个途径涉及直接由二嗪生成的二丙基卡宾，其他途径归因于4-重氮庚烷的离子和光化学反应以及归二嗪前体的激发态。用一个简单的捕集阱可以很容易地截获二丙基卡宾。该方法的产率受到前体形成卡宾的效率的限制。

  DOI：

  10.1016/s0040-4039(99)00356-1

文献信息

• MULTI-ARM TARGETING ANTI-CANCER CONJUGATE
  申请人：BrightGene Bio-Medical Technology Co., Ltd.

  公开号：US20210008218A1

  公开（公告）日：2021-01-14

  A multi-branched dnig conjugate of formula (I) or a pharmaceutically acceptable salt thereof. In the formula, R is an organic center, POLY is a polymer, L is a multivalent linker, T is a targeting molecule, D is an active agent, and q is any integer between 3 and 8. The symbol “*” in L represents a junction point of the multivalent linker L and the targeting molecule T, “#” represents a junction point of the multivalent linker L and the active agent D, and “%” represents a junction point of the multivalent linker L and POLY. 1 is any integer between 2 and 20, and m and n are each an integer between 0 and 10. T is iRGD, cRGD, tLyp-1, Lyp-1, RPARPAR, Angiopep2, or GE11. D is a camptothecin drug.

  公式（I）的多支链药物结合物或其药学上可接受的盐。在公式中，R是一个有机中心，POLY是一种聚合物，L是一种多价连接剂，T是一种靶向分子，D是一种活性药物，q是介于3和8之间的任意整数。L中的符号“*”表示多价连接剂L和靶向分子T的连接点，“＃”表示多价连接剂L和活性药物D的连接点，“％”表示多价连接剂L和POLY的连接点。1是介于2和20之间的任意整数，m和n分别是介于0和10之间的整数。T是iRGD，cRGD，tLyp-1，Lyp-1，RPARPAR，Angiopep2或GE11。D是一种喜树碱类药物。
• Compounds and Methods For Treatment of Thrombosis
  申请人：Deng Hongfeng

  公开号：US20080146811A1

  公开（公告）日：2008-06-19

  The invention provides compounds, pharmaceutical compositions, and methods for the treatment of thromboembolic disorders, such as, for example, arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, or thromboembolic disorders in the chambers of the heart.

  本发明提供了用于治疗血栓栓塞性疾病的化合物、制药组合物和方法，例如，动脉心血管血栓栓塞性疾病、静脉心血管血栓栓塞性疾病或心脏房室的血栓栓塞性疾病。
• Sulfopyrroles
  申请人：Eberle Martin

  公开号：US20070060570A1

  公开（公告）日：2007-03-15

  The invention relates to compounds of formula (I) wherein R 1 represents aryl, aralkyl or heteroaryl, R 2 is aryl or heteroaryl and R 3 is aryl, heteroaryl or optionally substituted aminomethyl, to methods of synthesis of such compounds, to pharmaceutical compositions containing compounds of formula (I), to the use of a compounds of formula (I) for the preparation of a pharmaceutical composition for the treatment of neoplastic and autoimmune diseases, and to methods of treatment of neoplastic and autoimmune diseases using compounds of formula (I) or of pharmaceutical compositions containing same.

  本发明涉及式(I)化合物，其中R1代表芳基、芳基烷基或杂芳基，R2为芳基或杂芳基，R3为芳基、杂芳基或可选取代的氨甲基；本发明还涉及合成这类化合物的方法，含有式(I)化合物的制药组合物，使用式(I)化合物制备用于治疗肿瘤和自身免疫性疾病的制药组合物，以及使用式(I)化合物或含有其的制药组合物治疗肿瘤和自身免疫性疾病的方法。
• Immunomodulating Heterocyclic Compounds
  申请人：Matthews Ian Richard

  公开号：US20090312334A1

  公开（公告）日：2009-12-17

  Compounds of formula (I) are inhibitors of CD80 and useful in immunomodulation therapy: wherein R 1 and R 3 independently represent H; F; Cl; Br; —NO 2 ; —CN; C 1 -C 6 alkyl optionally substituted by F or Cl; or C 1 -C 6 alkoxy optionally substituted by F; R 4 represents a carboxylic acid group (—COOH) or an ester thereof, or —C(═O)NR 6 R 7 , —NR 7 C(═O)R 6 , —NR 7 C(═O)OR 6 , —NHC(═O)NR 7 R 6 or —NHC(═S)NR 7 R 6 wherein R 6 represents H, or a radical of formula -(Alk) m -Q wherein m is 0 or 1, Alk is an optionally substituted divalent straight or branched C 1 -C 12 alkylene, or C 2 -C 12 alkenylene, or C 2 -C 12 alkynylene radical or a divalent C 3 -C 12 carbocyclic radical, any of which radicals may contain one or more —O—, —S— or —N(R 8 )— links wherein R 8 represents H or C 1 -C 4 alkyl, C 3 -C 4 alkenyl, C 3 -C 4 alkynyl, or C 3 -C 6 cycloalkyl, and Q represents H; —NR 9 R 10 wherein R 9 and R 10 independently represents H; C 1 -C 4 alkyl; C 3 -C 4 alkenyl; C 3 -C 4 alkynyl; C 3 -C 6 cycloalkyl; an ester group; an optionally substituted carbocyclic or heterocyclic group; or R 9 and R 10 form a ring when taken together with the nitrogen to which they are attached, which ring is optionally substituted; and R 7 represents H or C 1 -C 6 alkyl; or when taken together with the atom or atoms to which they are attached R 6 and R 7 form an optionally substituted monocyclic heterocyclic ring having 5, 6 or 7 ring atoms; and X represents a bond or a divalent radical of formula -(Z) n -(Alk)- or -(Alk)-(Z) n - wherein Z represents —O—, —S— or —NH—, Alk is as defined in relation to R 6 and n is 0 or 1.

  公式（I）的化合物是CD80的抑制剂，可用于免疫调节治疗：其中，R1和R3分别表示H; F; Cl; Br; -NO2; -CN; C1-C6烷基，所述烷基可选地被F或Cl取代; 或C1-C6烷氧基，所述烷氧基可选地被F取代; R4表示羧酸基(-COOH)或其酯，或-C（═O）NR6R7，-NR7C（═O）R6，-NR7C（═O）OR6，-NHC（═O）NR7R6或-NHC（═S）NR7R6，其中R6表示H，或式-(Alk)m-Q的基团，其中m为0或1，Alk是可选地取代的二价直链或支链C1-C12烷基，或C2-C12烯基，或C2-C12炔基基团或二价C3-C12环烷基基团，其中任何一个基团可以含有一个或多个-O-，-S-或-N（R8）-键，其中R8表示H或C1-C4烷基，C3-C4烯基，C3-C4炔基或C3-C6环烷基，而Q表示H; -NR9R10，其中R9和R10独立地表示H; C1-C4烷基; C3-C4烯基; C3-C4炔基; C3-C6环烷基; 酯基; 可选地取代的环烷基或杂环基; 或者R9和R10与它们所连接的氮一起形成一个环，该环是可选地取代的; 而R7表示H或C1-C6烷基; 或者当R6和R7与它们所连接的原子或原子一起形成一个可选地取代的含5、6或7个环原子的单环杂环时; 而X表示键或式-(Z)n-(Alk)-或-(Alk)-(Z)n-的二价基团，其中Z表示-O-，-S-或-NH-，Alk如在R6中所定义，n为0或1。
• AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY
  申请人：Shenzhen Targetrx, Inc.

  公开号：EP3492462A1

  公开（公告）日：2019-06-05

  An amino pyrimidine compound for inhibiting protein tyrosine kinase activity, a pharmaceutical composition thereof, preparation therefor, and an application hereof. Specifically, an amino pyrimidine compound represented by formula (I), R1, R2, L, Y, R6, W, A, m, and n being defined in the specification, and a pharmaceutically acceptable salt, a stereoisomer, a solvent compound, a hydrate, a polymorphism, a prodrug, or an isotope variant thereof. The compound can be used for treating and/or preventing protein tyrosine kinase-related diseases such as cell proliferative diseases, cancers, and immune diseases.

  一种抑制蛋白酪氨酸激酶活性的氨基嘧啶化合物、其药物组合物、制剂及其应用。具体地说，一种由式（I）代表的氨基嘧啶化合物，R1、R2、L、Y、R6、W、A、m 和 n 在说明书中定义，以及其药学上可接受的盐、立体异构体、溶剂化物、水合物、多晶型、原药或同位素变体。该化合物可用于治疗和/或预防蛋白酪氨酸激酶相关疾病，如细胞增殖性疾病、癌症和免疫疾病。